BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brandi G, Rizzo A, Dall’olio FG, Felicani C, Ercolani G, Cescon M, Frega G, Tavolari S, Palloni A, De Lorenzo S, Abbati F, Mollica V, Ricci AD, Serra C. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. International Journal of Hyperthermia 2020;37:479-85. [DOI: 10.1080/02656736.2020.1763484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang W, Luo C, Zhang ZY, Zhang BX, Chen XP. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review. Front Immunol 2022;13:1079342. [PMID: 36700218 DOI: 10.3389/fimmu.2022.1079342] [Reference Citation Analysis]
2 Savchenko IV, Breder VV, Stilidi IS, Laktionov KK, Kudashkin NE, Egorova AV, Chulkova SV. Second line drug therapy for biliary cancer. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-22-136-147] [Reference Citation Analysis]
3 Wang Y, Strazzabosco M, Madoff DC. Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice? Curr Oncol Rep 2022;24:1741-50. [PMID: 36255606 DOI: 10.1007/s11912-022-01338-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang T, Xu C, Xu D, Yang X, Liu Y, Li X, Li Z, Dang N, Lv Y, Zhang Z, Li L, Ye K. Integrating cell interaction with transcription factors to obtain a robust gene panel for prognostic prediction and therapies in cholangiocarcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.981145] [Reference Citation Analysis]
5 Zhang X, Ma H, Li T, Huang B, Jia N, Meng Y. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma. Clin Transl Oncol 2022. [DOI: 10.1007/s12094-022-02979-5] [Reference Citation Analysis]
6 He MY, Yan FF, Cen KL, Shen P. Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature. World J Clin Cases 2022; 10(32): 11889-11897 [DOI: 10.12998/wjcc.v10.i32.11889] [Reference Citation Analysis]
7 Zhao J, Guo Y, Ding W, Han G, Jiang C, Yang C, Hu Y, Zhang L, Wu C, Ni M, Kong X, Huang T, Zhang C, Xia Y. Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study. Front Oncol 2022;12:965711. [DOI: 10.3389/fonc.2022.965711] [Reference Citation Analysis]
8 Zhang B, Yao W. Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients. World J Surg Oncol 2022;20:320. [PMID: 36171621 DOI: 10.1186/s12957-022-02783-z] [Reference Citation Analysis]
9 Li F, Jiang Y, Jiang L, Li Q, Yan X, Huang S, Chen J, Yuan S, Fu Y, Liu J. Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:957792. [DOI: 10.3389/fonc.2022.957792] [Reference Citation Analysis]
10 Zhu Q, Zhai S, Ge E, Li L, Jiao X, Xiong J, Zhu G, Xu Y, Qu J, Wang Z. Intrahepatic cholangiocarcinoma with gastric metastasis misdiagnosed as primary gastric cancer: A case report and literature review. Front Oncol 2022;12:997735. [DOI: 10.3389/fonc.2022.997735] [Reference Citation Analysis]
11 Yu H, Xu Y, Gao W, Li M, He J, Deng X, Xing W. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. Front Oncol 2022;12:930611. [DOI: 10.3389/fonc.2022.930611] [Reference Citation Analysis]
12 Wang J, Zhang B, Cheng X, Li Q, Lv H, Nie C, Chen B, Xu W, Zhao J, He Y, Tu S, Chen X, Yang D. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors. Journal of Oncology 2022;2022:1-8. [DOI: 10.1155/2022/4233782] [Reference Citation Analysis]
13 Sapisochin G, Ivanics T, Heimbach J. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time? Hepatology 2022;75:455-72. [PMID: 34859465 DOI: 10.1002/hep.32258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
14 Kovač JD, Janković A, Đikić-rom A, Grubor N, Antić A, Dugalić V. Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI. Current Oncology 2022;29:698-723. [DOI: 10.3390/curroncol29020061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Yakovlev D, Shiryaev A, Farrakhova D, Savelieva T, Efendiev K, Loshchenov M, Zhemerikin G, Amouroux M, Daul C, Blondel W, Reshetov I, Loschenov V. Comparison of the Capabilities of Spectroscopic and Quantitative Video Analysis of Fluorescence for the Diagnosis and Photodynamic Therapy Control of Cholangiocellular Cancer. Photonics 2022;9:65. [DOI: 10.3390/photonics9020065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gonzalez-Carmona MA, Möhring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, Bolch M, Vogt A, Kaczmarek DJ, Heling DJ, Dold L, Nattermann J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Mohr RU, Weismüller TJ. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Sci Rep 2022;12:1011. [PMID: 35046437 DOI: 10.1038/s41598-021-04297-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Yan X, Zhuang LP, Ning ZY, Wang P, Meng ZQ. Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34937481 DOI: 10.1080/17474124.2022.2021067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Yang S, Lin H, Song J. Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis. Cancer Cell Int 2021;21:681. [PMID: 34923980 DOI: 10.1186/s12935-021-02365-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Gritskevich AA, Gurmikov BN, Baitman TP, Shipilova AN, Paichadze AA, Chzhao AV. Cholangiocarcinogenesis and targeted therapy for cholangiocarcinoma. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-20-101-109] [Reference Citation Analysis]
20 Fabritius MP, Ben Khaled N, Kunz WG, Ricke J, Seidensticker M. Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma-Role of Interventional Radiology. J Clin Med 2021;10:5574. [PMID: 34884275 DOI: 10.3390/jcm10235574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Paprottka KJ, Galiè F, Ingrisch M, Geith T, Ilhan H, Todica A, Michl M, Nadjiri J, Paprottka PM. Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors. Cancers (Basel) 2021;13:5399. [PMID: 34771563 DOI: 10.3390/cancers13215399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? Expert Rev Gastroenterol Hepatol 2021;15:1239-40. [PMID: 34449276 DOI: 10.1080/17474124.2021.1974296] [Reference Citation Analysis]
24 Li H, Chen L, Zhu GY, Yao X, Dong R, Guo JH. Interventional Treatment for Cholangiocarcinoma. Front Oncol 2021;11:671327. [PMID: 34268114 DOI: 10.3389/fonc.2021.671327] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Ricci AD, Rizzo A, Bonucci C, Tavolari S, Palloni A, Frega G, Mollica V, Tober N, Mazzotta E, Felicani C, Serra C, Brandi G. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo 2020;34:3421-9. [PMID: 33144450 DOI: 10.21873/invivo.12181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
26 Chu HH, Kim JH, Shin YM, Won HJ, Kim PN. Percutaneous Radiofrequency Ablation for Recurrent Intrahepatic Cholangiocarcinoma After Curative Resection: Multivariable Analysis of Factors Predicting Survival Outcomes. AJR Am J Roentgenol 2021;217:426-32. [PMID: 34076458 DOI: 10.2214/AJR.20.23461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Rizzo A. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas) 2021;57:458. [PMID: 34066684 DOI: 10.3390/medicina57050458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020;17:441-452. [PMID: 32859625 DOI: 10.21873/cgp.20203] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 33.0] [Reference Citation Analysis]
29 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
30 Rizzo A, Ricci AD, Frega G, Di Federico A, Brandi G. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Rev Gastroenterol Hepatol 2021;15:567-74. [PMID: 33787429 DOI: 10.1080/17474124.2021.1911646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Wu T, Jiang X, Zhang X, Wu B, Xu B, Liu X, Zheng L, Wang Y. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Cancer Control 2021;28:1073274821989314. [PMID: 33618536 DOI: 10.1177/1073274821989314] [Reference Citation Analysis]
32 Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 2021;15:547-54. [DOI: 10.1080/17474124.2021.1890031] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 20.5] [Reference Citation Analysis]
33 Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel) 2021;13:558. [PMID: 33535621 DOI: 10.3390/cancers13030558] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 38.0] [Reference Citation Analysis]
34 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 27.5] [Reference Citation Analysis]
35 Beal EW, Cloyd JM, Pawlik TM. Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. J Clin Med 2020;10:E104. [PMID: 33396821 DOI: 10.3390/jcm10010104] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
36 Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer Control 2020;27:1073274820983013. [PMID: 33356500 DOI: 10.1177/1073274820983013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Shen T, Zheng S, Geng L, Liu Z, Xu J, Lin B, Qian J, Zheng S. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. Technol Cancer Res Treat 2020;19:1533033820979703. [PMID: 33308041 DOI: 10.1177/1533033820979703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, Ikezawa H, Hayata N, Nakajima R, Morizane C. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer 2020;20:1105. [PMID: 33198671 DOI: 10.1186/s12885-020-07365-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
39 Rizzo A, Tavolari S, Ricci AD, Frega G, Palloni A, Relli V, Salati M, Fenocchio E, Massa A, Aglietta M, Brandi G. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers (Basel) 2020;12:E3256. [PMID: 33158162 DOI: 10.3390/cancers12113256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Wang T, Zhang J, Wang W, Yang X, Kong J, Shen S, Wang W. Development and Validation of Nomograms for Predicting Cancer-Specific Survival in Elderly Patients with Intrahepatic Cholangiocarcinoma After Liver Resection: A Competing Risk Analysis. Cancer Manag Res 2020;12:11015-29. [PMID: 33173335 DOI: 10.2147/CMAR.S272797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Rahban D, Doostan M, Salimi A. Cancer Therapy; Prospects for Application of Nanoparticles for Magnetic-Based Hyperthermia. Cancer Invest 2020;38:507-21. [PMID: 32870068 DOI: 10.1080/07357907.2020.1817482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
42 Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? Medicines (Basel) 2020;7:E54. [PMID: 32878011 DOI: 10.3390/medicines7090054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]